Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 24;22(1):122.
doi: 10.3390/ijms22010122.

Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin's Lymphomas from Genome-Wide Association Studies

Isaias Hernández-Verdin  1   2 , Karim Labreche  1   2 , Marion Benazra  1   2   3   4   5 , Karima Mokhtari  6   7 , Khê Hoang-Xuan  1   2   3   4   7   8 , Agusti Alentorn  1   2   3   4   7
Affiliations
Review

Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin's Lymphomas from Genome-Wide Association Studies

Isaias Hernández-Verdin et al. Int J Mol Sci. .

Abstract

B-cell non-Hodgkin's lymphoma (NHL) risk associations had been mainly attributed to family history of the disease, inflammation, and immune components including human leukocyte antigen (HLA) genetic variations. Nevertheless, a broad range of genome-wide association studies (GWAS) have shed light into the identification of several genetic variants presumptively associated with B-cell NHL etiologies, survival or shared genetic risk with other diseases. The present review aims to overview HLA structure and diversity and summarize the evidence of genetic variations, by GWAS, on five NHL subtypes (diffuse large B-cell lymphoma DLBCL, follicular lymphoma FL, chronic lymphocytic leukemia CLL, marginal zone lymphoma MZL, and primary central nervous system lymphoma PCNSL). Evidence indicates that the HLA zygosity status in B-cell NHL might promote immune escape and that genome-wide significance variants can give biological insight but also potential therapeutic markers such as WEE1 in DLBCL. However, additional studies are needed, especially for non-DLBCL, to replicate the associations found to date.

Keywords: B-cell non-Hodgkin’s lymphoma; GWAS; HLA; cancer risk.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic map of the human leukocyte antigen (HLA) genomic region showing the distribution of HLA genes along with the summarized mechanism of antigen presentation.
See this image and copyright information in PMC

References

    1. Al-Naeeb A.B., Ajithkumar T., Behan S., Hodson D. Non-Hodgkin lymphoma. BMJ. 2018;362:k3204. doi: 10.1136/bmj.k3204. - DOI - PubMed
    1. Hoang-Xuan K., Bessell E., Bromberg J.E.C., Hottinger A.F., Preusser M., Rudà R., Schlegel U., Siegal T., Soussain C., Abacioglu U., et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: Guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16:e322–e332. doi: 10.1016/S1470-2045(15)00076-5. - DOI - PubMed
    1. Smedby K.E. Epidemiology and etiology of non-Hodgkin lymphoma—A review. Acta Oncol. 2006;45:258–271. doi: 10.1080/02841860500531682. - DOI - PubMed
    1. Parihar A.S., Singh R., Shaik S., Negi B.S., Rajguru J.P., Patil P.B., Sharma U. Non-Hodgkin’s lymphoma: A review. J. Fam. Med. Prim. Care. 2020;9:1834–1840. doi: 10.4103/jfmpc.jfmpc_1037_19. - DOI - PMC - PubMed
    1. Swerdlow S.H., Campo E., Pileri S.A., Harris N.L., Stein H., Siebert R., Advani R., Ghielmini M., Salles G.A., Zelenetz A.D., et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390. doi: 10.1182/blood-2016-01-643569. - DOI - PMC - PubMed

MeSH terms